Patentscope RSS feed

Automated sample changer for nuclear magnetic resonance spectrometer (Tue, 23 May 1978)
An automated sample changer, controlled by gas fluidic circuitry, integrated with a Nuclear Magnetic Resonance (NMR) spectrometer provides a means for sequentially transferring samples to and from such spectrometer without an attendant to control such transfer. Such a changer comprises a means for holding a series of samples, a robot arm cooperating with such holding means and disposed in alignment with the sample receiving tube of an NMR spectrometer, a gas fluidic circuit to sense the required action, and a second gas fluidic circuit integrated therewith to provide the energy to make the transfer.
>> Read More

PSEUDOMYCIN ANALOGS (Wed, 23 Jan 2002)
The invention relates to pseudomycin natural products including pseudomycins A' and B', methods for making such pseudomycins, and methods employing antifungal activity of these pseudomycins. NMR and mass spectrometry indicate formula (IA) for pseudomycin A'. NMR and mass spectrometry indicate formula (IB) for pseudomycin B'.
>> Read More

METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR PREDICTING RESPONSIVENESS TO A PHARMACEUTICAL THERAPY FOR OBESITY OR EVALUATING INVESTIGATIONAL PHARMACEUTICAL AGENTS (Thu, 09 Jul 2009)
Methods, systems, and computer program products using TRL V6 as a biomarker for the modulation of triglyceride and/or lipoprotein metabolism in a mammal induced by an investigational weight loss pharmaceutical agent. The biomarker may be used for predetermining if an individual patient will likely respond favorably to a given weight loss pharmaceutical agent and/or for testing a pharmaceutical agent s ability to modulate triglyceride and/or lipoprotein metabolism in a mammal.
>> Read More

Methods, systems and computer program products for predicting responsiveness to a pharmaceutical therapy for obesity or evaluating investigational pharmaceutical agents (Thu, 03 Jun 2010)
Methods, systems, and computer program products using TRL V6 as a biomarker for the modulation of triglyceride and/or lipoprotein metabolism in a mammal induced by an investigational weight loss pharmaceutical agent. The biomarker may be used for predetermining if an individual patient will likely respond favorably to a given weight loss pharmaceutical agent and/or for testing a pharmaceutical agent s ability to modulate triglyceride and/or lipoprotein metabolism in a mammal.
>> Read More

PSEUDOMYCIN NATURAL PRODUCTS (Thu, 26 Oct 2000)
The invention relates to pseudomycin natural products including pseudomycins A' and B', methods for making such pseudomycins, and methods employing antifungal activity of these pseudomycins. NMR and mass spectrometry indicate formula (IA) for pseudomycin A'. NMR and mass spectrometry indicate formula (IB) for pseudomycin B'.
>> Read More

METHOD FOR PREDICTING WEIGHT GAIN ASSOCIATED WITH A PHARMACEUTICAL THERAPY (Thu, 27 Jan 2011)
Methods for using TRL V6 as a biomarker for the risk of weight gain associated with treatment of a patient with a pharmaceutical agent, as for example, olanzapine.
>> Read More

Unknown (Fri, 14 Mar 1986)
These compounds, said to be selective leukotriene antagonists, are of the formula:. or the pharmaceutically acceptable salts thereof in which R1 is H, C1-6 alkyl, C3-8 cycloalkyl, or phenyl; R2 is H, C1-6 alkyl, or C2-6 alkenyl; R3 is H, C1-10 alkyl, phenyl, C1-10 alkyl-substituted phenyl, biphenyl, or benzylphenyl; R4 is -COOR7, -CONR8R9, -CONHOH, -NR8R9, -SC(=NH)NH2, cyano, cyanothio, in which R7 is H or C1-4 alkyl; R8 and R9 are each independently H, C1-3 alkyl, or taken together with the nitrogen atom to which they are attached, form a morpholine or N-methyl piperazine ring; R is H, C1-4 alkyl or -CH2COOR7; p is O, 1 or 2; R5 and R6 are each independently H or C1-3 alkyl; and n is 0-10.
>> Read More

A54145 antibiotics and process for their production (Tue, 19 Feb 1991)
New peptide antibiotic A54145, individual A54145 components A, A.sub.1, B, B.sub.1, C, D, E and F and their pharmaceutically acceptable salts, are useful antibacterial agents which also improve growth performance in animals, especially poultry. Biologically pure cultures of the A54145-producing Streptomyces fradiae cultures NRRL 18158, NRRL 18159 and NRRL 18160 cultures and methods of making antibiotic A54145 using those cultures are also provided.
>> Read More

Pseudomycin natural products (Thu, 08 Apr 2004)
The invention relates to pseudomycin natural products including pseudomycins A′ and B′, methods for making such pseudomycins, and methods employing antifungal activity of these pseudomycins. NMR and mass spectrometry indicate formula (I) for pseudomycin A′. NMR and mass spectrometry indicate formula (II) for pseudomycin B′.embedded image
>> Read More

Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide (Thu, 08 Jul 2010)
Crystalline R-2-(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-y1)-propionamide and methods of its preparation and use are disclosed.
>> Read More

METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR PREDICTING RESPONSIVENESS TO A PHARMACEUTICAL THERAPY FOR OBESITY OR EVALUATING INVESTIGATIONAL PHARMACEUTICAL AGENTS (Thu, 21 Oct 2010)
Methods, systems, and computer program products using TRL V6 as a biomarker for the modulation of triglyceride and/or lipoprotein metabolism in a mammal induced by an investigational weight loss pharmaceutical agent. The biomarker may be used for predetermining if an individual patient will likely respond favorably to a given weight loss pharmaceutical agent and/or for testing a pharmaceutical agent's ability to modulate triglyceride and/or lipoprotein metabolism in a mammal.
>> Read More

GLYCOPEPTIDE ANTIBIOTICS (Wed, 27 Apr 1988)
New glycopeptide antibiotic A82846, comprising A82846A, A82846B and A82846C, is produced by Nocardia orientalis strains NRRL 18098, NRRL 18099 and NRRL 18100. The A82846 antibiotics have activity against Gram-positive bacteria comparable to that of vancomycin.
>> Read More

Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis (Thu, 06 Aug 1998)
Disclosed are compounds which inhibit $g(b)-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed pharmaceutical compositions comprising a compound which inhibits $g(b)-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
>> Read More

METHODS, SYSTEMS AND COMPUTER PROGRAM PRODUCTS FOR PREDICTING RESPONSIVENESS TO A PHARMACEUTICAL THERAPY FOR OBESITY OR EVALUATING INVESTIGATIONSL PHARMACEUTICAL AGENTS (Thu, 09 Jul 2009)
Methods, systems, and computer program products using TRL V6 as a biomarker for the modulation of triglyceride and/or lipoprotein metabolism in a mammal induced by an investigational weight loss pharmaceutical agent. The biomarker may be used for predetermining if an individual patient will likely respond favorably to a given weight loss pharmaceutical agent and/or for testing a pharmaceutical agent s ability to modulate triglyceride and/or lipoprotein metabolism in a mammal.
>> Read More

PREPARATION OF CEPHALOSPORIN COMPOUNDS (Thu, 06 Apr 1972)
1,269,697. Silylated cephalosporin derivatives. ELI LILLY & CO. 22 Aug., 1969 [23 Aug., 1968], No. 42066/69. Heading C2A. [Also in Division C3] Novel silylated cephalosporin derivatives of Formula VI wherein R11 is hydrogen or acetoxy, and R1, R2 and R3 are each hydrogen or a C 1 to C 8 hydrocarbon radical free from aliphatic unsaturation, with not more than two of R1 , R2 and R3 bonded to the same silicon atom being hydrogen, and R10 is hydrogen or the group: are prepared by reacting 7-aminocephalosporanic acid or 7-amino-desacetoxycephalosporanic acid or a salt thereof, with a mono- or bissilylamide of one of the Formulµ I to V wherein R1, R2 and R3 are as defined above; R5 and R9 are each hydrogen or C 1 to C 8 hydrocarbon free from aliphatic unsaturation, R8 is C 1 to C 8 hydrocarbon free from aliphatic unsaturation; each of R4, R6 and R7 is hydrogen or C 1 to C 8 hydrocarbon free from aliphatic unsaturation, or R6 and R7 together with the common nitrogen complete a heterocyclic ring containing 5 to 6 ring-forming atoms, one of which can be oxygen para to the nitrogen, or 4 to 6 ring-forming carbons provided that R6 and R7 together contain not more than 18 carbons and that if R6 is alkyl with tert. carbon bonded to the nitrogen then R7 is hydrogen; or R4 and R6 together with the attached nitrogens and the carbonyl group form a heterocyclic ring containing 5 to 6 ring-forming atoms and 2 to 3 methylene ring-forming carbon atoms; and Y is a C 3 to C 18 alkylene group with a 3 to 5 carbon chain between the nitrogen and the carbonyl group to which Y is bonded, the reaction being effected in an anhydrous aprotic solvent at - 25‹ to +50‹ C. The invention includes a composition comprising (a) a compound of Formula VI above, (b) a silylamide of one of Formulµ I to V above and (c) an anhydrous solvent for (a) and (b) of which the molecules do not contain Zerewitinoff hydrogen. The silylated cephalosporins may be converted to known antibiotically active cephalosporins by reacting with an appropriate acylating agent to give the corresponding N-acylated silyl ester which is treated with a C 1 to C 6 alkanol to give the required cephalosporin which is recovered from the solution preferably as the Na or K salt. Cephalothin, cephaloglycin and cephalexin are prepared in this way.
>> Read More

Pseudomycin natural products (Tue, 07 Oct 2003)
The invention relates to pseudomycin natural products including pseudomycins A′ and B′, methods for making such pseudomycins, and methods employing antifungal activity of these pseudomycins. NMR and mass spectrometry indicate a formula for pseudomycin A′ of:embedded image NMR and mass spectrometry indicate a formula for pseudomycin B′ of:embedded image
>> Read More

CRYSTALLINE (R)-2-(4-CYCLOPROPANESULPHONYL-PHENYL)-N-PYRAZIN-2-YL-3-(TETRAHYDROPYRAN-4-YL)-PROPIONAMIDE (Thu, 23 Jul 2009)
Crystalline R-2-(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3- -(tetrahydropyran-4-yl)-propionamide and methods of its preparation and use are disclosed.
>> Read More

PROCESS FOR PREPARING A DESACETOXYCEPHALOSPORIN COMPOUND AND 3-NITROOXYCEPHAM COMPOUNDS (Wed, 05 Feb 1975)
1382947 Reacting 3-halocepham compounds ELI LILLY & CO 18 June 1973 [30 June 1972 (2)] 28800/73 Heading C2C A process for treating a cepham compound comprises reacting a cepham compound of Formula I with AgQ to obtain a mixture comprising a compound of Formula II a compound of Formula III and a compound of Formula IV wherein R is the residue of an imide derived from a dicarboxylic acid, R 1 is a carboxy protecting group, X is chlorine or bromine and Q is -ONO 2 or wherein R 2 is C 1-4 alkyl or C 5-6 cyclo-alkyl. The compound of Formula III may be converted by heating to 80 # 175‹ C. into the compound of Formula II. The following treatments are exemplified (1) the reaction between p-nitrobenzyl 7 - phthalimido - 3 - methyl - 3#- chlorocepham-4-carboxylate and silver nitrate to form a mixture of p-nitrobenzyl 7-phthalimido- 3 - methyl - 3# - nitroxycepham - 4 - carboxylate, p - nitrobenzyl 6 - phthalimido - 2amethyl - 2# - nitrooxymethyl penam - 3 - carboxylate and p-nitrobenzyl-7-phthalimido-3- methyl - 3 - cepham - 4 - carboxylate, (ii) modifications of (i) wherein the starting material is the p-methoxy- and not the p-nitro-cepham compound, (iii) p-methoxybenzyl 7-phthalimido- 3 - methyl - 3# - nitroxy cepham-4 - carboxylate prepared in (ii) is converted by heating to methoxybenzyl 7-phthalimido-3-methyl-3-cepham-4-carboxylate, (iv) modification of (i) wherein the starting material is the methyl and not the p-nitrobenzyl cepham compound, (v) methyl 7 - phthaleimido - 3 - methyl - 3#- nitro-oxycepham-4-carboxylate is converted by heating to methyl 7-phthalimido-3-methyl-3- cepham-4-carboxylate, and (vi) modification of (iv) wherein silver acetate is used instead of silver nitrate.
>> Read More

CRYSTALLINE FORMS OF GEMCITABINE AMIDE PRODRUG, COMPOSITIONS AND USE THEREOF (Wed, 08 Apr 2009)
The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using.
>> Read More

4-Desacetoxy-3-hydroxyvinblastine (Tue, 16 Mar 1976)
4-Desacetoxy-3'-hydroxyvinblastine, a novel indoledihydroindole alkaloid obtained in small quantities from Vinca rosea, intermediate for the preparation of antimitotic compounds.
>> Read More